News
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
GSK Plc said a blood cancer drug it had to pull from the market after a trial failure has shown promising results when combined with another cancer treatment. Skip to content.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback